SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. The company also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC, to develop and commercialize rights for SCY-078. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SCYX
Previous Symbol
CUSIPN/A
Phone201-884-5485
Debt
Debt-to-Equity Ratio0.27
Current Ratio4.53
Quick Ratio4.53
Price-To-Earnings
Trailing P/E Ratio-0.49
Forward P/E Ratio-0.82
P/E GrowthN/A
Sales & Book Value
Annual Sales$260,000.00
Price / Sales90.41
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.74 per share
Price / Book0.66
Profitability
EPS (Most Recent Fiscal Year)($1.01)
Net Income$-25,060,000.00
Net Margins-8,592.97%
Return on Equity-102.52%
Return on Assets-52.26%
Miscellaneous
Employees19
Outstanding Shares47,970,000
Market Cap$24.94 million
OptionableOptionable
SCYNEXIS (NASDAQ:SCYX) Frequently Asked Questions
What is SCYNEXIS's stock symbol?
SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."
How were SCYNEXIS's earnings last quarter?
SCYNEXIS Inc (NASDAQ:SCYX) announced its quarterly earnings data on Tuesday, November, 13th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.17) by $0.18. The business earned $0.06 million during the quarter, compared to the consensus estimate of $0.06 million. SCYNEXIS had a negative net margin of 8,592.97% and a negative return on equity of 102.52%. View SCYNEXIS's Earnings History.
When is SCYNEXIS's next earnings date?
What price target have analysts set for SCYX?
7 analysts have issued 1 year price targets for SCYNEXIS's shares. Their predictions range from $4.00 to $9.00. On average, they expect SCYNEXIS's share price to reach $5.2857 in the next year. This suggests a possible upside of 978.7% from the stock's current price. View Analyst Price Targets for SCYNEXIS.
What is the consensus analysts' recommendation for SCYNEXIS?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SCYNEXIS.
What are Wall Street analysts saying about SCYNEXIS stock?
Here are some recent quotes from research analysts about SCYNEXIS stock:
- 1. According to Zacks Investment Research, "SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina. " (10/18/2018)
- 2. Canaccord Genuity analysts commented, "We’d use any weakness in SCYX shares to build long term positions ahead of a pivotal VVC read and what could be positive data from preliminary FURI and CARES reads expected later this year." (8/14/2018)
- 3. Maxim Group analysts commented, "Scynexis reported 2Q18 with operating expenses of $7.7M and ended the period with $55M in cash, runway at the current burn rate into late 2019." (8/10/2018)
Has SCYNEXIS been receiving favorable news coverage?
Media coverage about SCYX stock has been trending somewhat positive recently, according to InfoTrie. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. SCYNEXIS earned a news impact score of 1.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the near term.
Who are some of SCYNEXIS's key competitors?
Some companies that are related to SCYNEXIS include Evofem Biosciences (EVFM), MOTIF BIO PLC/S (MTFB), Cumberland Pharmaceuticals (CPIX), Chiasma (CHMA), Axsome Therapeutics (AXSM), Scpharmaceuticals (SCPH), VBI Vaccines (VBIV), Teligent (TLGT), PhaseBio Pharmaceuticals (PHAS), Aridis Pharmaceuticals (ARDS), Sienna Biopharmaceuticals (SNNA), Tetraphase Pharmaceuticals (TTPH), Pharmaxis (PXSLY), Entasis Therapeutics (ETTX) and Immune Design (IMDZ).
Who are SCYNEXIS's key executives?
SCYNEXIS's management team includes the folowing people:
- Dr. Marco Taglietti, CEO, Pres & Director (Age 58)
- Mr. Eric Francois, Chief Financial Officer (Age 43)
- Mr. David Gonzalez Angulo, Chief Medical Officer (Age 53)
- Mr. Scott Sukenick J.D., Gen. Counsel & Corp. Sec. (Age 40)
- Dr. Rajeshwar Motheram, VP of Pharmaceutical Devel.
Who are SCYNEXIS's major shareholders?
SCYNEXIS's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (0.94%) and Private Advisor Group LLC (0.43%). Company insiders that own SCYNEXIS stock include David C Hastings, Eric Francois, Gonzalez David Angulo, Marco Taglietti and Scott Sukenick. View Institutional Ownership Trends for SCYNEXIS.
Which institutional investors are buying SCYNEXIS stock?
SCYX stock was acquired by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC and Private Advisor Group LLC. Company insiders that have bought SCYNEXIS stock in the last two years include David C Hastings, Eric Francois, Gonzalez David Angulo, Marco Taglietti and Scott Sukenick. View Insider Buying and Selling for SCYNEXIS.
How do I buy shares of SCYNEXIS?
Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is SCYNEXIS's stock price today?
One share of SCYX stock can currently be purchased for approximately $0.49.
How big of a company is SCYNEXIS?
SCYNEXIS has a market capitalization of $24.94 million and generates $260,000.00 in revenue each year. The company earns $-25,060,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. SCYNEXIS employs 19 workers across the globe.
What is SCYNEXIS's official website?
How can I contact SCYNEXIS?
SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The company can be reached via phone at 201-884-5485 or via email at [email protected]
MarketBeat Community Rating for SCYNEXIS (NASDAQ SCYX)
MarketBeat's community ratings are surveys of what our community members think about SCYNEXIS and other stocks. Vote "Outperform" if you believe SCYX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCYX will underperform the S&P 500 over the long term. You may vote once every thirty days.
